EMERGING ROLES FOR NOVEL ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA

Clozapine for the Treatment-Resistant Schizophrenic

1988 • 4,030 citations

J Neuropsychiatry Clin Neurosci

1992 • 3,756 citations

What are the functional consequences of neurocognitive deficits in schizophrenia?

1996 • 3,505 citations

Psychopharmacology: The third generation of progress

1988 • 3,403 citations

Glycine potentiates the NMDA response in cultured mouse brain neurons

1987 • 3,116 citations

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1976 • 2,224 citations

Molecular pathology of schizophrenia: more than one disease process?

1980 • 1,877 citations

Antipsychotic drug doses and neuroleptic/dopamine receptors

1976 • 1,623 citations

Deficit and nondeficit forms of schizophrenia: the concept

1988 • 1,307 citations

Neurological Anatomy. In Relation to Clinical Medicine.

1970 • 1,250 citations

Risperidone in the treatment of schizophrenia

1994 • 1,205 citations

The Journal of Neuropsychiatry and Clinical Neurosciences

1992 • 1,058 citations

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

1996 • 1,047 citations

The current status of the dopamine hypothesis of schizophrenia

1988 • 962 citations

The Pharmacologic Basis of Therapeutics

1981 • 949 citations

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1997 • 906 citations

A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients

1993 • 884 citations

Duration of psychosis and outcome in first-episode schizophrenia

1992 • 878 citations

Neuroleptics and the Natural Course of Schizophrenia

1991 • 777 citations

A Survey of Drug-Induced Extrapyramidal Reactions

1961 • 756 citations

Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins

1992 • 665 citations

National Institute of Mental Health Longitudinal Study of Chronic Schizophrenia

1991 • 639 citations

Memory and cognitive function in man

1977 • 624 citations

Drugs and the treatment of psychiatric disorders

1996 • 581 citations

Part III. Speculations on the Processes That Underlie Schizophrenic Symptoms and Signs

1974 • 572 citations

Further Evidence for Dementia of the Prefrontal Type in Schizophrenia?

1987 • 524 citations

Treatment of Negative Symptoms

1985 • 500 citations

Antischizophrenic Drugs and Brain Cholinergic Receptors

1974 • 474 citations

The pathophysiology of extrapyramidal side-effects of neuroleptic drugs

1980 • 445 citations

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

1988 • 429 citations

Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia

1986 • 420 citations

The Mechanism of Action of Novel Antipsychotic Drugs

1991 • 410 citations

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine

1993 • 403 citations

Biochemical profile of risperidone, a new antipsychotic.

1988 • 393 citations

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia

1994 • 391 citations

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

1994 • 380 citations

Cognitive Deficits in Schizophrenia

1993 • 371 citations

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

1989 • 357 citations

Clinical and Biologic Response to Clozapine in Patients With Schizophrenia

1992 • 356 citations

Amelioration of negative symptoms in schizophrenia by glycine

1994 • 349 citations

Negative Symptoms in Schizophrenia: Their Longitudinal Course and Prognostic Importance

1985 • 344 citations

Natural History of Schizophrenia Subtypes

1991 • 331 citations

Neuropsychological functioning of first-episode schizophreniform patients

1992 • 324 citations

Phenothiazine Treatment in Acute Schizophrenia

1964 • 321 citations

The Effects of Clozapine on Tardive Dyskinesia

1991 • 304 citations

PHENOTHIAZINE TREATMENT IN ACUTE SCHIZOPHRENIA; EFFECTIVENESS: THE NATIONAL INSTITUTE OF MENTAL HEALTH PSYCHOPHARMACOLOGY SERVICE CENTER COLLABORATIVE STUDY GROUP.

1964 • 303 citations

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study

1992 • 302 citations

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1997 • 302 citations

The Risks and Benefits of Clozapine versus Chlorpromazine

1987 • 299 citations

Update on the Clinical Efficacy and Side Effects of Clozapine

1991 • 298 citations

Psychopharmacologic Treatment of Schizophrenia

1993 • 283 citations

Tolerability and therapeutic effect of clozapine

1985 • 277 citations

ICI 204,636, an Atypical Antipsychotic

1996 • 275 citations

Neuroleptics: Effects on Neuropsychological Function in Chronic Schizophrenic Patients

1990 • 275 citations

The dementia of dementia praecox

1978 • 274 citations

Seroquel: biochemical profile of a potential atypical antipsychotic

1993 • 271 citations

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

1989 • 271 citations

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1995 • 268 citations

The Positive-Negative Distinction in Schizophrenia

1992 • 268 citations

Dimensions of Outcome with Clozapine

1992 • 256 citations

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

1989 • 256 citations

Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia

1996 • 253 citations

The effect of long‐term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years

1988 • 249 citations

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1995 • 238 citations

3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors

1981 • 229 citations

Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia.

1994 • 216 citations

The role of 5-HT2A receptors in antipsychotic activity

1995 • 209 citations

Neurobiological substrates of tardive dyskinesia: the GABA hypothesis

1984 • 209 citations

Risperidone: clinical safety and efficacy in schizophrenia.

1992 • 208 citations

The effects of neuroleptics on neuropsychological test results of schizophrenics

1988 • 200 citations

Schizophrenia with Good and Poor Outcome. I: Early Clinical Features, Response to Neuroleptics and Signs of Organic Dysfunction

1985 • 196 citations

The Effect of Neuroleptics on Cognitive and Psychomotor Function

1990 • 191 citations

The Pathophysiologic Basis of Tardive Dyskinesia

1980 • 190 citations

"Negative Symptoms": Conceptual and Methodological Problems

1985 • 186 citations

Institutionalism and Schizophrenia: A Comparative Study of Three Mental Hospitals 1960-1968.

1971 • 179 citations

Social Adjustment and Cognitive Performance of High-Risk Children

1985 • 178 citations

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1993 • 177 citations

Prospective Study of Tardive Dyskinesia Incidence in the Elderly

1991 • 172 citations

Domains of Psychopathology

1994 • 171 citations

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1996 • 162 citations

Tardive dyskinesia

1988 • 162 citations

Relations among clinical scales in schizophrenia

1991 • 153 citations

Testing Systems for Assessment of Negative Symptoms in Schizophrenia

1992 • 152 citations

The Prevalence of Tardive Dyskinesia

1991 • 149 citations

Atypical antipsychotic drugs and long-term outcome in schizophrenia.

1996 • 145 citations

Receptor-Binding Profiles of Neuroleptics

1985 • 144 citations

The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in Schizophrenia

1986 • 143 citations

Drug-induced dystonia

1975 • 142 citations

Clinical profile of clozapine: Adverse reactions and agranulocytosis

1992 • 141 citations

Does clozapine cause tardive dyskinesia?

1993 • 140 citations

Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.

1996 • 139 citations

Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia

1996 • 135 citations

Neuroleptic-induced akathisia: a review

1989 • 135 citations

Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.

1984 • 131 citations

Dyskinesia. Research and treatment.

1985 • 126 citations

Randomized, Double-Blind, Controlled Trial of Risperidone Versus Clozapine in Patients With Chronic Schizophrenia

1995 • 122 citations

Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.

1996 • 121 citations

Neuroleptic drug effects on cognitive function in schizophrenia

1990 • 121 citations

Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.

1987 • 119 citations

Leponex ? associated granulocytopenia: a review of the situation

1989 • 118 citations

Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade.

1996 • 117 citations

Clozapine--a new antipsychotic agent.

1974 • 116 citations

Performance of Schizophrenic Patients on Putative Neuropsychological tests of frontal Lobe Function

1988 • 113 citations

An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET

1988 • 112 citations

Clozapine's effect on negative symptoms in treatment-refractory schizophrenics

1994 • 112 citations

Understanding the Mechanism of Action of Atypical Antipsychotic Drugs

1993 • 110 citations

Clozapine Eligibility Among State Hospital Patients

1996 • 107 citations

5-HT2 Antagonist Ritanserin in Neuroleptic-Induced Parkinsonism

1990 • 105 citations

Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia

1991 • 100 citations

Double-blind Comparison of Risperidone and Haloperidol in Schizophrenic and Schizoaffective Psychoses

1993 • 99 citations

Clozapine--a potential antipsychotic agent without extrapyramidal manifestations.

1974 • 98 citations

The deficit state in first-episode schizophrenia

1994 • 98 citations

The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis

1989 • 96 citations

The Syndrome of Schizophrenia: Unresolved Questions and Opportunities for Research

1980 • 94 citations

Antagonism of phencyclidine-induced hyperactivity by glycine in mice

1986 • 94 citations

Prevalence and severity of akathisia in patients on clozapine

1991 • 93 citations

Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain

1995 • 91 citations

Schizophrenia with Good and Poor Outcome

1986 • 90 citations

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

1994 • 88 citations

Attention and higher cortical functions in schizophrenia

1991 • 86 citations

Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: Acute and repeated treatment

1992 • 86 citations

The Effect of Risperidone on Cognition in Patients with Schizophrenia

1996 • 86 citations

The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse ? implications for psychosis

1995 • 85 citations

Clozapine — A Novel Antipsychotic Agent

1991 • 80 citations

Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.

1992 • 78 citations

New Drugs for the Treatment of Schizophrenia

1993 • 78 citations

[3H]MDL 100,907: a novel selective 5-HT2A receptor ligand

1996 • 77 citations

Neuroleptic Side Effects: Acute Extrapyramidal Syndromes and Tardive Dyskinesia

1988 • 74 citations

The role of excitatory amino acids in neuropsychiatric illness

1990 • 70 citations

Recent advances in the pharmacotherapy of schxzophrenia

1994 • 70 citations

Treatment of drug-induced psychosis in Parkinson's disease with clozapine.

1993 • 69 citations

The effects of neuroleptics on neuropsychological test results of schizophrenics

1988 • 69 citations

Pilot Clinical Investigation of Risperidone in the Treatment of Psychotic Patients

1990 • 69 citations

Risperidone

1994 • 67 citations

Motor and mental aspects of acute extrapyramidal syndromes

1994 • 67 citations

LYMPHOCYTE ABNORMALITY IN CHRONIC MUCOCUTANEOUS CANDIDIASIS

1970 • 65 citations

Recent advances in schizophrenia

1990 • 64 citations

The Effect of Risperidone on Cognition in Patients with Schizophrenia

1996 • 63 citations

Harakiri: a clinical study of deliberate self-stabbing.

1994 • 61 citations

Cognitive impairment as a target for pharmacological treatment in schizophrenia

1995 • 60 citations

RISPERIDONE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS: AN INTERNATIONAL DOUBLE-BLIND PARALLEL-GROUP STUDY VERSUS HALOPERIDOL.

1992 • 59 citations

Prediction of Improvement in Schizophrenia Under Four Phenothiazines

1967 • 57 citations

Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat

1995 • 57 citations

The pathophysiologic basis of tardive dyskinesia.

1978 • 54 citations

Review of Adverse Effects of Psychotropic Drugs.

1995 • 53 citations

Negative symptoms: diagnosis, treatment and prognosis

1996 • 52 citations

Recent Advances in Schizophrenia

1990 • 51 citations

Memory Impairment in Schizophrenia: Perspectives from Psychopathology and Pharmacotherapy

1996 • 51 citations

Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia

1992 • 49 citations

Positive and negative symptoms covary during clozapine treatment in schizophrenia

1993 • 49 citations

Prospective study of tardive dyskinesia in the elderly

1990 • 48 citations

The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings.

1986 • 47 citations

Sensorimotor and Cognitive Performance of Schizophrenic Inpatients Treated with Haloperidol, Flupenthixol, or Clozapine

1988 • 46 citations

Review of recent studies

1996 • 46 citations

The Effect of the Partial Dopamine Agonist Terguride on Negative Symptoms in Schizophrenics

1988 • 44 citations

Prediction of Response to Phenothiazines in Schizophrenia

1972 • 43 citations

The biology of schizophrenia

1982 • 42 citations

Memory Impairment in Schizophrenia: Perspectives from Psychopathology and Pharmacotherapy

1996 • 41 citations

Pharmacologic properties of (?)-3PPP (preclamol) in man

1992 • 41 citations

Cognitive functioning in chronically hospitalized schizophrenic patients: age-related changes and age disorientation as a predictor of impairment

1995 • 41 citations

RISPERIDONE: CLINICAL DEVELOPMENT: NORTH AMERICAN RESULTS

1992 • 41 citations

Antianxiety therapy: potential value of long-term treatment.

1987 • 40 citations

Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.

1989 • 40 citations

PHARMACOLOGICAL PROFILE OF THE ATYPICAL NEUROLEPTIC SERTINDOLE

1992 • 36 citations

II. Impairments in Schizophrenics in Cross-sectional and Longitudinal Perspective — The Mannheim Experience in Two Independent Samples

1989 • 36 citations

Clozapine and jaw dyskinesia: a case report.

1991 • 32 citations

Memory and intelligence in lateralized temporal lobe epilepsy and schizophrenia

1995 • 31 citations

Negative Symptoms as a Risk Factor for Tardive Dyskinesia in Schizophrenia

1993 • 30 citations

Clinical handbook of antipsychotic drug therapy

1980 • 30 citations

The WHO Psychological Impairments Rating Schedule (WHO/PIRS). II. Impairments in Schizophrenics in cross-sectional and longitudinal perspective--the Mannheim experience in two independent samples.

1989 • 29 citations

Adverse Effects of Psychotropic Drugs

1995 • 28 citations

B-HT920 - A Novel Dopamine Autoreceptor Agonist in the Treatment of Patients with Schizophrenia

1990 • 28 citations

Memory function in schizophrenia

1994 • 27 citations

Regional selectivity of neuroleptic drugs: An argument for site specificity

1983 • 25 citations

The New Pharmacotherapy of Schizophrenia

1997 • 24 citations

Predicting rehospitalization at a community mental health center: A „double-crossed” validation

1984 • 23 citations

The Heterogeneity of Memory Dysfunction in Schizophrenia

1996 • 23 citations

Psychopharmacologic treatment of negative schizophrenic symptoms

1994 • 22 citations

The Effect of OPC-4392, a Partial Dopamine Receptor Agonist on Negative Symptoms: Results of an Open Study

1988 • 21 citations

P-4-73 A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia

1995 • 21 citations

[An unusual syndrome in the oral region caused by administration of megaphen].

1956 • 21 citations

Comparison of short-term administration of sertindole, clozapine and haloperidol on the inactivation of midbrain dopamine neurons in the rat

1994 • 20 citations

PARTIAL BENZODIAZEPINE AGONISTS IN SCHIZOPHRENIA: EXPECTATIONS AND PRESENT CLINICAL FINDINGS

1992 • 17 citations

Clinical Handbook of Antipsychotic Drug Therapy

1981 • 17 citations

The new pharmacotherapy of schizophrenia

1996 • 16 citations

Clozapine Treatment of Schizophrenia

1995 • 16 citations

Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-Substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles

1992 • 16 citations

Race/ethnicity patterns in the homicide of children in Los Angeles, 1980 through 1989.

1993 • 15 citations

Neuropharmacology of the extrapyramidal system

1988 • 13 citations

Remoxipride in Parkinsonʼs Disease

1995 • 12 citations

Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum.

1989 • 12 citations

Assessing cognitive function in schizophrenics and patients with Alzheimer's disease

1995 • 10 citations

Efficacy of clozapine vs haloperidol in a long term clinical trial: Preliminary findings

1995 • 10 citations

Recent Advances in Pharmacotherapy of Schizophrenia

1993 • 9 citations

Drugs in central nervous system disorders

1985 • 9 citations

Predictors of Employment Status of Treated Patients With DSM-III-R dIagnosis. Can Logistic Regression Model Find a Solution?

1994 • 9 citations

Drugs in Central Nervous System Disorders

1986 • 8 citations

Tardive dyskinesia status: stability or change.

1988 • 8 citations

Effects of seroquel™, clozapine and other putative atypical antipsychotic agents in primate models of dystonia

1995 • 6 citations

Compte rendu du Congrès

1903 • 4 citations

An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients

1993 • 4 citations

Compte-Rendu du Congrès

1902 • 3 citations

Steatomous Thickening of the Parietes of the Bladder

1836 • 1 citations

Deleted Work

1955 • 0 citations